COVID-19
As a research-driven company, we are part of the collective effort in fighting COVID-19. Learn more about our ongoing engagement in the fight against COVID-19
Search
Reinhold
People with type 2 diabetes have an increased risk of heart disease and this can have a profound impact on their everyday lives
Dedifferentiated liposarcoma (DDLPS)
An aggressive subtype of a category of cancers called soft tissue sarcoma (STS). DDLPS has a poor prognosis and limited treatment options.
Discover your hidden talent with BI Open – the new platform for data science enthusiasts
Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.
Heart Diseases in humans and animals
Humans and animals are more alike than different. Having a heart disease can affect us similarly, and the way to prevent it can work for all as well.
Heart murmur in dogs: symptoms and how to treat it
Monitoring your dog’s heart can save its life
Largest European development center for biotechnology
Boehringer Ingelheim inaugurates largest European development center for biotechnology
Spotlight on GPP
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
Leticia develops product medical strategies
Leticia develops product medical strategies at Boehringer Ingelheim. For more talent insights, visit our Careers Page.
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
CHMP recommends new treatment for chronic kidney disease
The CHMP of EMA has granted a positive opinion recommending empagliflozin for the treatment of adults with chronic kidney disease
Digital solution for individualized diabetes care
With Exandra™, we have developed a clinical decision support tool for diabetes care to make everyday life easier for healthcare professionals.
Streetvet: Free veterinary care
Learn more about StreetVet free veterinarian care for companion animals of the homeless
New cancer research building: Boosting innovation in oncology
With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
How dangerous is the mpox virus?
Mpox, formerly known as monkeypox: What exactly is this virus, how is it transmitted, and what are the most noticeable symptoms?
MASH
MASH
DiaTEC new purification technology Ingelvac CircoFLEX
Boehringer Ingelheim introduces DiaTEC, a new and proprietary purification technology for Ingelvac CircoFLEX®
Brigitte Fuhr
Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.
Xochimilco
The site in Xochimilco, Mexico, focuses on pharmaceutical production for both Human Pharma and Animal Health.
Generalized pustular psoriasis (GPP): a chronic inflammatory disease
Learn more about this chronic inflammatory disease associated with skin and systemic symptoms
Careers: Winning with people
Our employees are the foundation of our innovative strength. We continue to put people first in everything we do and support our employees in the key moments of their careers.
Facts About Asthma
Understand more about what asthma is, how asthma is diagnosed and what you can do to reduce symptoms in your day to day life.
FIBRONEER™ Phase III program initiated
FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
1990-2023: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2023, with milestones
Transforming Science Day Europe
Oct. 2, 2023: Join us in London, or virtually, to learn more about our patient-centric approach to innovation, advancing pipeline and partnering approach.